Log in

NASDAQ:HJLI - Hancock Jaffe Laboratories Stock Price, Forecast & News

$0.52
+0.01 (+1.96 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$0.50
Now: $0.52
$0.63
50-Day Range
$0.47
MA: $0.62
$0.80
52-Week Range
$0.44
Now: $0.52
$3.45
Volume94,566 shs
Average Volume131,451 shs
Market Capitalization$9.32 million
P/E RatioN/A
Dividend YieldN/A
Beta1.14
Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HJLI
CUSIPN/A
Phone949-261-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$190,000.00
Book Value$0.17 per share

Profitability

Net Income$-13,040,000.00
Net Margins-5,293.30%

Miscellaneous

EmployeesN/A
Market Cap$9.32 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive HJLI News and Ratings via Email

Sign-up to receive the latest news and ratings for HJLI and its competitors with MarketBeat's FREE daily newsletter.


Hancock Jaffe Laboratories (NASDAQ:HJLI) Frequently Asked Questions

What is Hancock Jaffe Laboratories' stock symbol?

Hancock Jaffe Laboratories trades on the NASDAQ under the ticker symbol "HJLI."

How were Hancock Jaffe Laboratories' earnings last quarter?

Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) released its earnings results on Thursday, October, 31st. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.04. Hancock Jaffe Laboratories had a negative return on equity of 224.86% and a negative net margin of 5,293.30%. View Hancock Jaffe Laboratories' Earnings History.

When is Hancock Jaffe Laboratories' next earnings date?

Hancock Jaffe Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Hancock Jaffe Laboratories.

What price target have analysts set for HJLI?

1 equities research analysts have issued 1-year target prices for Hancock Jaffe Laboratories' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Hancock Jaffe Laboratories' stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 476.9% from the stock's current price. View Analyst Price Targets for Hancock Jaffe Laboratories.

What is the consensus analysts' recommendation for Hancock Jaffe Laboratories?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hancock Jaffe Laboratories in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hancock Jaffe Laboratories.

What are Wall Street analysts saying about Hancock Jaffe Laboratories stock?

Here are some recent quotes from research analysts about Hancock Jaffe Laboratories stock:
  • 1. Maxim Group analysts commented, "Hancock Jaffe announced positive 90-day results from its animal feasibility for CoreoGraft, its off-the-shelf conduit for Coronary Artery Bypass Grafting (CABG)." (8/15/2019)
  • 2. According to Zacks Investment Research, "Hancock Jaffe Laboratories, Inc. is involved in developing and manufacturing bioprosthetic medical devices to treat cardiac and vascular diseases. Its product candidates consists of the porcine tissue based VenoValve, which is intended to be surgically implanted in the deep venous system of the leg to treat Chronic Venue Insufficiency; CoreoGraftÒ, a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery and a porcine tissue based heart valve, is an ideal candidate for pediatric aortic/mitral valve replacement. Hancock Jaffe Laboratories, Inc. is based in IRVINE, United States. " (6/26/2019)

Has Hancock Jaffe Laboratories been receiving favorable news coverage?

Media headlines about HJLI stock have been trending extremely positive on Saturday, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hancock Jaffe Laboratories earned a news impact score of 4.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Hancock Jaffe Laboratories.

Are investors shorting Hancock Jaffe Laboratories?

Hancock Jaffe Laboratories saw a increase in short interest during the month of November. As of November 15th, there was short interest totalling 55,800 shares, an increase of 100.7% from the October 31st total of 27,800 shares. Based on an average daily volume of 43,800 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.5% of the shares of the stock are sold short. View Hancock Jaffe Laboratories' Current Options Chain.

Who are some of Hancock Jaffe Laboratories' key competitors?

What other stocks do shareholders of Hancock Jaffe Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hancock Jaffe Laboratories investors own include Amarin (AMRN), Avid Bioservices (CDMO), Ford Motor (F), General Electric (GE), Teva Pharmaceutical Industries (TEVA), Achillion Pharmaceuticals (ACHN), Akari Therapeutics (AKTX), Advanced Micro Devices (AMD), Atossa Genetics (ATOS) and Activision Blizzard (ATVI).

Who are Hancock Jaffe Laboratories' key executives?

Hancock Jaffe Laboratories' management team includes the folowing people:
  • Mr. Robert A. Berman, CEO & Director (Age 56)
  • Mr. Robert Rankin, CFO, Sec. & Treasurer (Age 66)
  • Dr. Benedict Broennimann M.D., Chief Medical Officer of Outside of United States (Age 62)
  • Dr. Marc H. Glickman, Sr. VP & Chief Medical Officer (Age 70)
  • Mr. Warren Hancock, Co-founder

When did Hancock Jaffe Laboratories IPO?

(HJLI) raised $8 million in an initial public offering on Thursday, May 31st 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Network 1 Financial Securities acted as the underwriter for the IPO and ViewTrade Securities was co-manager.

How do I buy shares of Hancock Jaffe Laboratories?

Shares of HJLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hancock Jaffe Laboratories' stock price today?

One share of HJLI stock can currently be purchased for approximately $0.52.

How big of a company is Hancock Jaffe Laboratories?

Hancock Jaffe Laboratories has a market capitalization of $9.32 million and generates $190,000.00 in revenue each year. View Additional Information About Hancock Jaffe Laboratories.

What is Hancock Jaffe Laboratories' official website?

The official website for Hancock Jaffe Laboratories is http://www.hancockjaffe.com/.

How can I contact Hancock Jaffe Laboratories?

Hancock Jaffe Laboratories' mailing address is 70 DOPPLER, IRVINE CA, 92618. The company can be reached via phone at 949-261-2900.


MarketBeat Community Rating for Hancock Jaffe Laboratories (NASDAQ HJLI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Hancock Jaffe Laboratories and other stocks. Vote "Outperform" if you believe HJLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HJLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel